Constantiam Biosciences

We are building a B2B computational platform to address the bottleneck of clinical genetic variant interpretation for actionable medical management.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Boston, MA, USA
  • Currency USD
  • Founded September 2020
  • Employees 3
  • Incorporation Type C-corp
  • Website constantiambio.com

Company Summary

We are a B2B subscription service, and we charge an annual, per-seat license fee for use of our applications. We plan to build a stable base of clinical geneticist customers within our beachhead market of genetic testing companies. Our value proposition is to reduce the time needed for clinical geneticists to leverage valuable high-throughput functional evidence by 90%. Current practices for utilizing functional evidence are manual, and tedious.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free